Board of Directors
click on pictures for contact details
Siro Perez, PhD, MFin – Co-Founder & CEO
Siro has over 15 years of international experience in new technology R&D, commercialisation, and investment. He actively advises and cofounds start-ups through Roundcape, a boutique advisory firm. Previously, he served as CEO of ToxiMet, leading the company from a development stage start-up to a fully commercial enterprise with sales in 5 continents, and raising £5m at increasing valuations in the process. Before, he worked investing in life sciences at leading hedge and VC funds, as Project Leader at The Boston Consulting Group, and leading a group in drug development at Novartis. Siro holds a Masters in Finance from London Business School, a PhD summa cum laude in Molecular Biology from the Autonoma University of Madrid, and studied Computer Science Engineering at UNED. He speaks English, German, and Spanish.
Prof Kirill Alexandrov – Co-Founder & CSO
Kirill is an academic and serial entrepreneur with over 25 years of experience in molecular and synthetic biology. MW is the product of his work at the Institute for Molecular Bioscience and the Australian Institute for Bioengineering and Nanotechnology of the University of Queensland, backed by over $10m in research funding. In 1998 he co-founded the successful German biotechnology company JenaBioscience, and in 2006 he conceptualised, raised funds, established and operated the Dortmund Protein Expression (DPF) facility that was the most advanced European protein production facility at the time. Previously, he was a group leader at the Department of Physical Biochemistry at the Max- Planck Institute, Germany. Kirill has numerous patented inventions in the area of protein expression and engineering. He has a PhD in Cell Biology from European Molecular Biology Laboratory in Heidelberg, Germany.
Charles Holroyd – NED & Remco Chairman
Charles Holroyd is the Group Business Development Director for Oxford Instruments plc, a leading nanotechnology tools provider for research and industrial customers worldwide. Charles is responsible for the Oxford Instruments’ M&A activity, where he has led and completed 22 M&A transactions, including the £175 million acquisition of publicly quoted Andor Technologies plc in 2014. Charles is a Fellow of the Institution of Engineering Technologists, and was educated at Bristol University and at INSEAD Business School in France.
click on pictures for contact details
Lindy Murphy, PhD – Director of Development
Lindy has over 15 years of industrial experience in R&D of electrochemical biosensors for diagnostic applications. Prior to joining Molecular Warehouse, she worked for six years developing electrochemical sensors for point-of-care detection of drug substances. Previously, she worked for six years at Oxford Biosensors, where her work on disposable point-of-care sensors for cardiac risk resulted in nine patents. She started her industrial R&D career at Drew Scientific, where she developed a disposable renal panel of sensors combining both potentiometric and amperometric approaches, leading to two patents. She holds a chemistry degree and a PhD in electrochemical biosensors, both from the Department of Chemistry, Imperial College.
Sebastien Cuvelier, BEng., MBA – Director of Technology
Sebastien brings 18 years of experience developing sensor electronics and medical devices, having extensive experience operating in medical regulatory environment including ISO13485, 6060, 61010, 62304 medical software and ISO9001. Previously to MW, he was system architect for the design and development of the OrganOx metra, a CE marked device for conservation of organs for transplant, as well as for a closed-loop Class III system to continually monitor patients response to drug intervention during clinical trials. Sebastien has a BEng (Hons) in Electronics and Computer Engineering, and an MBA, both from Brighton University.
Marcus Gould, D.Phil, C.Biol, C.Sci – Director of Quality & Regulatory Affairs
Throughout his career Marcus has worked for a number of start-up device companies and established multi-national companies encompassing all aspects of CE mark, FDA, and ISO 13485 activities. Marcus’s experience includes both pre-market and post-market activities, and he devises and implements regulatory strategies for CE Marking and US FDA IDE and 510(k) applications. Prior to Molecular Warehouse Marcus was Regulatory Manager for GlySure Ltd, where he was responsible for obtaining the CE mark for their continuous glucose monitoring system, and IDE approval for a pivotal US based clinical study. Marcus has obtained CE Marking approval for a range of medical devices ranging in complexity and technology from advanced infusion pumps and associated administration sets and implantable glucose sensors to a range in vitro diagnostic (IVD) devices, and has designed, implemented and maintained ISO 13485 accreditation, and compliance to Directives 2011/65/EU (RoHS2), and 2012/19/EU (WEEE). Marcus holds a doctorate in biochemistry (microbiology) from the University of Oxford, holds both Chartered Biologist and Chartered Scientist status, and is a consultant editor for TOPRA’s monthly publication ‘Regulatory Rapporteur’.
Andrea Mica – Venture Capital Investor, Remco member
Andrea Mica is a Director at Oxford Technology, a specialized fund investing in early stage life sciences and technology startups. Prior to joining Oxford Technology he acquired extensive experience both promoting technologies for sale, and identifying new technologies to invest in. He also co-founded CleanSteel Ltd, a company for recycling waste products. He has an MSc in Industrial Design Engineering from Delft University, and went on for a further graduate study in Innovation and Creativity at the State University College of New York.
Ingrid Teigland Akay, MD, MBA – Venture Capital Investor
Ingrid Teigland Akay is the Founder and Managing Partner of Hadean Ventures, a specialised life sciences Venture Capital Fund. She is an entrepreneur and investment professional with experience within healthcare, consumer goods and technology. As a medical doctor, she gained broad clinical experience working in diverse fields such as general medicine, surgery and psychiatry, with exposure to both the public and private sector in several European countries including Scandinavia, Germany and the UK. As a venture capitalist, Ingrid has substantial experience from deal sourcing, investing, and supporting start-up companies globally in different phases of development, from R&D to commercial stage. Ingrid holds a medical degree from Medizinische Hochschule Hannover, Germany, and an MBA with finance concentration from London Business School.
Thomas Lonngren, PhD, MRPharmS, FCRP – Regulatory
Thomas is former Executive Director of the European Medicines Agency, EMA (Jan 01-Dec 10) and previously served with the Swedish Board of Health and Welfare as Director of Operations (1978-93) and later Deputy Director General at the Swedish Medical Products Agency (MPA), Läkemedelsverket (Jan 93 – Dec 00). Thomas established the EMA from a relatively small unknown agency in 2001 to a world-renowned leader in 2010 and was responsible for all of its operations and annual work flow. He is currently Director at his own independent consultancy
Justin Turner, QC, PhD – Intellectual Property
Justin Turner’s practice at 3 New Square is concerned with all areas of intellectual property and other technical commercial disputes. His background in immunology has resulted in the major part of his practice relating to pharmacology and biotechnology in a number of leading cases, representing clients such as Novartis, GSK, and BMS. He appears in the UK courts, the Court of Justice of the EU and the EPO. Justin holds a PhD in immunology from Cambridge, and a BSc in Veterinary Medicine from London University.
Bryce Carmine – Pharmaceuticals
Bryce retired as an executive VP at Eli Lilly & Co. and president of Lilly Bio-Medicines in 2011. Previously, he was executive VP, Global Marketing and Sales. Carmine joined Lilly in 1975 in New Zealand and later held several marketing and management positions NZ and in the U.S. before becoming general manager of a joint venture pharmaceutical company in South Korea. He subsequently managed the Lilly operations in Australia/NZ before becoming president of Eli Lilly Japan until 1999 when he was named President, Global Product Development.
Nigel Rowbotham – Angel Investor, Remco member
Following a 20 year career in interest rate and currency derivatives at Irving Trust, Bank of New York, and the London International Financial Futures Exchange (now owned by Intercontinental Exchange, Inc), Nigel is an experienced angel investor, with a focus on healthcare. He is an investor in Molecular Warehouse and a member of our Remuneration Committee. He has a BA (Hons) in Economics from Exeter University.
Richard Adams – Talent
Following an international career of 25 years with blue chip pharma companies, including Glaxo, Rhone Poulenc and Ciba–Geigy (Novartis), where he served in general management, sales, marketing and business development roles at local, regional and headquarters levels, Richard moved into a second career in International Executive Search and consulting in 1996. He has experience in OTC, Generics, Animal Health, Rx and medical devices, diagnostics and biotechnology in an Executive and NED Search Capacity.
Prof. David Taube – Imperial College London
Professor David Taube is one of the UK’s leading nephrologists and the UK’s only Professor of Transplant Medicine, and the Director of the Imperial College Academic Health Science Centre (AHSC). Prof Taube is the medical director at Imperial College Healthcare NHS Trust and Professor of Transplant Medicine at Imperial College London, and brings more than 25 years’ experience in research, education and clinical leadership to Molecular Warehouse.
Prof Raymond Vanholder – European Kidney Health Alliance
Prof. Vanholder is the Chair of the European Kidney Health Alliance, and Emeritus Professor at the University Hospital Ghent, in Belgium, where he served as Head of the Department of Nephrology for more than 30 years. Until 2011 he was a member of the Scientific Advisory Board of the European Renal Association – European Dialysis and Transplant Association (ERA – EDTA), an organisation he has been Distinguished Fellow of since 2011.
Sayeed Malek, MD, FACS – Brigham and Women’s Hospital Harvard
Dr. Sayeed Malek joined the Division of Transplant Surgery at Brigham and Women’s Hospital in 2006 and is currently the Clinical Director of Transplant Surgery. The primary focus of his research is the study of Racial and Ethnic Disparities in transplantation. He also serves on many regional and national committees including the New England Paired Kidney Exchange committee and the United Network for Organ Sharing (UNOS)/ Minority Affairs committee. Dr. Malek’s interests include living donor kidney transplantation and pancreas transplantation.
Prof. David Johnson, PSM – Princess Alexandra Hospital Brisbane
David Johnson is currently Medical Director of the Queensland Renal Transplant Service at Princess Alexandra Hospital, Brisbane, Australia, He is the principal investigator on a number of large, multi-centre randomised controlled trials, including the balANZ, HERO, IDEAL, IMPENDIA, HONEYPOT and CKD-FIX trials, and is chair of the Data Safety and Monitoring Board for the FINESSE trial. He has published over 600 original manuscripts in peer-reviewed journals and presented over 360 abstracts at national and international scientific meetings.
Prof. Atholl Johnston BSc, BA, MSc, PhD, CSci, ERT, FFPM, FBPharmacolS, FRCPath – Scientific Director ASI
Professor of Clinical Pharmacology at Barts and The London School of Medicine and Dentistry, Queen Mary University of London: visiting Professor of Forensic Pharmacology and Toxicology at St George’s, University of London and Scientific Director for ASI. Prof Johnston has more than 35 years’ experience in the measurement of drugs as a guide to therapy and has co-organised international laboratory proficiency testing schemes for the measurement of immunosuppressive drugs. He is author of over 250 articles in peer reviewed journals and has written Expert Reports on drug use and abuse for submission to the National Institute for Clinical Excellence (NICE), and several national drug regulatory agencies including the MHRA (UK), EMA (EU), FDA (USA), TGA (Aus) and Health Canada.